Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and neck cancer.